Molecular diagnostics and biomarkers in cholangiocarcinoma

Banales, 2020, Cholangiocarcinoma 2020: the next horizon in mechanisms and management, Nat. Rev. Gastroenterol. Hepatol., 17, 557, 10.1038/s41575-020-0310-z Yao, 2016, Increasing mortality in the United States from cholangiocarcinoma: an analysis of the national center for health statistics database, BMC Gastroenterol., 16, 117, 10.1186/s12876-016-0527-z Bergquist, 2015, Epidemiology of cholangiocarcinoma, Best Pract. Res. Clin. Gastroenterol., 29, 221, 10.1016/j.bpg.2015.02.003 Alabraba, 2019, Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged, Eur. J. Surg. Oncol., 45, 1660, 10.1016/j.ejso.2019.04.002 2021 Patrinos, 2009 Spring, 2016 Zheng, 2021, Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma, J. Gastrointest. Oncol., 10.21037/jgo-21-776 Labib, 2019, Molecular pathogenesis of cholangiocarcinoma, BMC Cancer, 19, 185, 10.1186/s12885-019-5391-0 Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N. Engl. J. Med., 362, 1273, 10.1056/NEJMoa0908721 Morita, 2018, Textbook of complex general surgical oncology Shirai, 2008, Perineural invasion is a prognostic factor in intrahepatic cholangiocarcinoma, World J. Surg., 32, 2395, 10.1007/s00268-008-9726-2 Ercolani, 2004, The role of lymphadenectomy for liver tumors, Ann. Surg., 239, 202, 10.1097/01.sla.0000109154.00020.e0 Kitagawa, 2001, Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection, Ann. Surg., 233, 385, 10.1097/00000658-200103000-00013 Amin, 2017, The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging, CA A Cancer J. Clin., 67, 93, 10.3322/caac.21388 Ebata, 2012, Hepatopancreatoduodenectomy for cholangiocarcinoma, Ann. Surg., 256, 297, 10.1097/SLA.0b013e31826029ca Hemming, 2010, Combined resection of the liver and pancreas for malignancy, J. Am. Coll. Surg., 210, 808, 10.1016/j.jamcollsurg.2009.12.007 Gamboa, 2020, The landmark series: gallbladder cancer, Ann. Surg Oncol., 27, 2846, 10.1245/s10434-020-08654-9 Shroff, 2019, Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline, J. Clin. Oncol., 37, 1015, 10.1200/JCO.18.02178 Primrose, 2019, Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study, Lancet Oncol., 20, 663, 10.1016/S1470-2045(18)30915-X Javle MM, Murugesan K, Shroff RT, et al. Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). https://doi.org/101200/JCO20193715_suppl4087. 2019;37(15_suppl):4087-4087. doi:10.1200/JCO.2019.37.15_SUPPL.4087. Jain, 2016, Molecular profiling of biliary tract cancer: a target rich disease, J. Gastrointest. Oncol., 7, 797, 10.21037/jgo.2016.09.01 Ross, 2015, Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations, 33 Lee, 2016, Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets, J. Clin. Pathol., 69, 403, 10.1136/jclinpath-2015-203394 Javle, 2016, Biliary cancer: utility of next-generation sequencing for clinical management, Cancer, 122, 3838, 10.1002/cncr.30254 Lowery, 2018, Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention, Clin. Cancer Res., 24, 4154, 10.1158/1078-0432.CCR-18-0078 Montal, 2020, Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma, J. Hepatol., 73, 315, 10.1016/j.jhep.2020.03.008 Silverman, 2021, Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib, Cancer Discov., 11, 326, 10.1158/2159-8290.CD-20-0766 Arai, 2014, Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology, 59, 1427, 10.1002/hep.26890 Presta, 2017, Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach, Pharmacol. Ther., 179, 171, 10.1016/j.pharmthera.2017.05.013 Nepal, 2018, Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma, Hepatology, 68, 949, 10.1002/hep.29764 Sia, 2015, Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma, Nat. Commun., 6, 1, 10.1038/ncomms7087 Churi, 2014, Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications, PLoS One, 9, 10.1371/journal.pone.0115383 Goeppert, 2019, Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma, Hepatology, 69, 2091, 10.1002/hep.30493 Farshidfar, 2017, Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles, Cell Rep., 18, 2780, 10.1016/j.celrep.2017.02.033 Saha, 2014, IDH mutations in liver cell plasticity and biliary cancer, Cell Cycle, 13, 3176, 10.4161/15384101.2014.965054 Mondesir, 2016, IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives, J. Blood. Med., 7, 171, 10.2147/JBM.S70716 Goyal, 2015, Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma, Oncol., 20, 1019, 10.1634/theoncologist.2015-0210 Yoshikawa, 2008, Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma, Br. J. Cancer, 98, 418, 10.1038/sj.bjc.6604129 Andersen, 2012, Genetic profiling of intrahepatic cholangiocarcinoma, Curr. Opin. Gastroenterol., 28, 266, 10.1097/MOG.0b013e3283523c7e Riener, 2008, Rare PIK3CA hotspot mutations in carcinomas of the biliary tract, Gene Chromosome Cancer, 47, 363, 10.1002/gcc.20540 Lamarca, 2018, The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers, PLoS One, 13, 10.1371/journal.pone.0206007 Zhao, 2021, ARID1A variations in cholangiocarcinoma: clinical significances and molecular mechanisms, Front. Oncol., 11 Luchini, 2017, PBRM1 loss is a late event during the development of cholangiocarcinoma, Histopathology, 71, 375, 10.1111/his.13234 Cardinale, 2015, Profiles of cancer stem cell subpopulations in cholangiocarcinomas, Am. J. Pathol., 185, 1724, 10.1016/j.ajpath.2015.02.010 Yamashita, 2013, Cancer stem cells in the development of liver cancer, J. Clin. Invest., 123, 1911, 10.1172/JCI66024 Zong, 2009, Notch signaling controls liver development by regulating biliary differentiation, Development, 136, 1727, 10.1242/dev.029140 Zender, 2013, A critical role for notch signaling in the formation of cholangiocellular carcinomas, Cancer Cell, 23, 784, 10.1016/j.ccr.2013.04.019 O'Rourke, 2020, Identification of a pan-gamma-secretase inhibitor response signature for notch-driven cholangiocarcinoma, Hepatology, 71, 196, 10.1002/hep.30816 Mettman, 2021, Refined pancreatobiliary UroVysion criteria and an approach for further optimization, Cancer Med., 10, 5725, 10.1002/cam4.4043 Barr Fritcher, 2015, An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples, Gastroenterology, 149, 1813, 10.1053/j.gastro.2015.08.046 Patrinos, 2017, Molecular diagnostics, 1 Aebersold, 2003, Mass spectrometry-based proteomics, Nature, 422, 198, 10.1038/nature01511 Emwas, 2019, NMR spectroscopy for metabolomics research, Metabolites, 9, 123, 10.3390/metabo9070123 Cassidy, 2005, Molecular imaging perspectives, J. R. Soc. Interface, 2, 133, 10.1098/rsif.2005.0040 Anderson, 2017, Current status and future challenges for molecular imaging, Philos Trans A Math Phys Eng Sci, 375 Liu, 2022, Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma, Insights Imaging, 13, 10.1186/s13244-021-01147-7 Chang, 2018, Synthesis and evaluation of ortho-[18F] fluorocelecoxib for COX-2 cholangiocarcinoma imaging, Drug Des. Dev. Ther., 12, 1467, 10.2147/DDDT.S161718 Werner, 2019, CXCR4-directed imaging in solid tumors, Front. Oncol., 9, 1 Yokoyama, 2016, Imaging hamster model of bile duct cancer in vivo using fluorescent l-glucose derivatives, Hum. Cell, 29, 111, 10.1007/s13577-015-0131-5 Yamada, 2007, A real-time method of imaging glucose uptake in single, living mammalian cells, Nat. Protoc., 2, 753, 10.1038/nprot.2007.76 Zhang, 2016, A cystine knot peptide targeting integrin α v β 6 for photoacoustic and fluorescence imaging of tumors in living subjects, J. Nucl. Med., 57, 1629, 10.2967/jnumed.115.169383 Catalano, 2013, Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study, Radiology, 269, 857, 10.1148/radiol.13131306 Huang, 2013, [123I]Iodooctyl fenbufen amide as a SPECT tracer for imaging tumors that over-express COX enzymes, Biomaterials, 34, 3355, 10.1016/j.biomaterials.2013.01.050 Li, 2003, Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy, Ann. Oncol., 14, 1274, 10.1093/annonc/mdg344 Kim, 2010, Differentiation of intraductal growing–type cholangiocarcinomas from nodular-type cholangiocarcinomas at biliary MR imaging with MR cholangiography, Radiology, 257, 364, 10.1148/radiol.10092105 Reichardt, 2005, Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model, Neoplasia, 7, 847, 10.1593/neo.05139 Polakova, 2016, Magnetic resonance cholangiopancreatography (MRCP) using new negative per-oral contrast agent based on superparamagnetic iron oxide nanoparticles for extrahepatic biliary duct visualization in liver cirrhosis, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub., 160, 512, 10.5507/bp.2016.046 Kim, 2004, Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging, J. Magn. Reson. Imag., 20, 612, 10.1002/jmri.20174 Taruno, 2019, Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparticles and a novel handheld magnetic probe, J. Surg. Oncol., 120, 1391, 10.1002/jso.25747 Han, 2021, Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial, Gastrointest. Endosc., 94, 569, 10.1016/j.gie.2021.03.027 Manzoni, 2018, Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences, Briefings Bioinf., 19, 286, 10.1093/bib/bbw114 Subrungruanga, 2013, Gene expression profiling of intrahepatic cholangiocarcinoma, Asian Pac. J. Cancer Prev. APJCP, 14, 557, 10.7314/APJCP.2013.14.1.557 Li, 2013, Gene expression patterns combined with bioinformatics analysis identify genes associated with cholangiocarcinoma, Comput. Biol. Chem., 47, 192, 10.1016/j.compbiolchem.2013.08.010 Dudley, 2016, Next-generation sequencing and fluorescence in situ hybridization have comparable performance characteristics in the analysis of pancreaticobiliary brushings for malignancy, J Mol Diagnostics, 18, 124, 10.1016/j.jmoldx.2015.08.002 Stewart, 2001, Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases, J. Clin. Pathol., 54, 449, 10.1136/jcp.54.6.449 Urban, 2019, Endoscopic perspective in cholangiocarcinoma diagnostic process, Gastroenterol Res Pract, 2019, 10.1155/2019/9704870 Kushnir, 2019, The diagnostic yield of malignancy comparing cytology, FISH, and molecular analysis of cell free cytology brush supernatant in patients with biliary strictures undergoing endoscopic retrograde cholangiography (erc): a prospective study, J. Clin. Gastroenterol., 53, 686, 10.1097/MCG.0000000000001118 Barr Fritcher, 2009, A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures, Gastroenterology, 136, 2180, 10.1053/j.gastro.2009.02.040 Singhi, 2020, Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures, Gut, 69, 52, 10.1136/gutjnl-2018-317817 Bankov, 2018, Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma, Clin. Transl. Gastroenterol., 9, 10.1038/s41424-018-0015-6 Syeda, 2020, Regulatory mechanism of MicroRNA expression in cancer, Int. J. Mol. Sci., 21 Peng, 2016, The role of MicroRNAs in human cancer, Signal Transduct. Target Ther., 1, 1 Dave, 2018, MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics, Lab. Investig ., 99, 452, 10.1038/s41374-018-0143-3 Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc. Natl. Acad. Sci. U. S. A., 105, 10513, 10.1073/pnas.0804549105 Sempere, 2014, Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?, Expert Rev. Mol. Diagn, 14, 853, 10.1586/14737159.2014.944507 Chen, 2008, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res., 18, 997, 10.1038/cr.2008.282 Wang, 2015, MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN, Oncotarget, 6, 5932, 10.18632/oncotarget.3465 Correa-Gallego, 2016, 11 Jiang, 2020, Identification of cholangiocarcinoma associated with hepatolithiasis via the combination of miRNA and ultrasound, Cancer Manag. Res., 12, 1845, 10.2147/CMAR.S241870 Cheng, 2015, Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma, Sci. Rep., 5, 10.1038/srep16103 Bernuzzi, 2016, Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma, Clin. Exp. Immunol., 185, 61, 10.1111/cei.12776 Loosen, 2019, Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma. Björkström NK, PLoS One, 14, 10.1371/journal.pone.0210944 Voigtländer, 2015, 10 Silakit, 2014, Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator, J. Hepatobil Pancreat. Sci., 21, 864, 10.1002/jhbp.145 Wang, 2015, Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma, Oncol. Rep., 33, 819, 10.3892/or.2014.3641 Wu, 2016, Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma, Tumor Biol., 37, 15019, 10.1007/s13277-016-5313-6 Sun, 2018, Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis, Cancer Manag. Res., 10, 2125, 10.2147/CMAR.S158155 Liang, 2016, Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma, Dig. Liver Dis., 48, 1227, 10.1016/j.dld.2016.07.006 Zhou, 2017, Identification of microRNAs as biomarkers for cholangiocarcinoma detection: a diagnostic meta-analysis, Clin .Res. Hepatol. Gastroenterol., 41, 156, 10.1016/j.clinre.2016.10.007 Silakit, 2017, Urinary microRNA-192 and microRNA-21 as potential indicators for liver fluke-associated cholangiocarcinoma risk group, Parasitol. Int., 66, 479, 10.1016/j.parint.2015.10.001 Li, 2020, Circular RNAs in cancer: biogenesis, function, and clinical significance, Trends in cancer, 6, 319, 10.1016/j.trecan.2020.01.012 Hansen, 2013, Natural RNA circles function as efficient microRNA sponges, Nature, 495, 384, 10.1038/nature11993 Memczak, 2013, Circular RNAs are a large class of animal RNAs with regulatory potency, Nature, 495, 333, 10.1038/nature11928 Louis, 2022, Emerging roles of circular RNAs in liver cancer, JHEP Reports, 4, 10.1016/j.jhepr.2021.100413 Zaborowski, 2015, Extracellular vesicles: composition, biological relevance, and methods of study, Bioscience, 65, 783, 10.1093/biosci/biv084 Lapitz, 2020, Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis, Cells, 9, 721, 10.3390/cells9030721 huang, 2016, Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin, J. Zhejiang Univ. - Sci. B, 17, 537, 10.1631/jzus.B1500266 Bai, 2020, The role of extracellular vesicles in cholangiocarcinoma, Cancer Cell Int., 20, 435, 10.1186/s12935-020-01526-y Yáñez-Mó, 2015, Biological properties of extracellular vesicles and their physiological functions, 4, 1 Yang, 2020, Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics, Theranostics, 10, 3684, 10.7150/thno.41580 Bridgewater, 2014, Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma, J. Hepatol., 60, 1268, 10.1016/j.jhep.2014.01.021 Scarà, 2015, CA 19-9: biochemical and clinical aspects, Adv. Exp. Med. Biol., 867, 247, 10.1007/978-94-017-7215-0_15 Liang, 2015, Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis, Med. Sci. Mon. Int. Med. J. Exp. Clin. Res., 21, 3555 Patel, 2000, The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis, Am. J. Gastroenterol., 95, 204, 10.1111/j.1572-0241.2000.01685.x Levy, 2005, The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis, Dig. Dis. Sci., 50, 1734, 10.1007/s10620-005-2927-8 Maeda, 1996, The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver, Mod. Pathol., 9, 901 Chapman Mrcp, 2011, Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer, J. Clin Exp. Hepatol., 1, 6, 10.1016/S0973-6883(11)60110-2 Takada, 1995, Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay, Br. J. Cancer, 71, 160, 10.1038/bjc.1995.33 Andreadis, 2005, Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy, J. Urol., 174, 1771, 10.1097/01.ju.0000176742.53556.25 Nakata, 1996, Clinical significance of serum CYFRA 21-1 in gastric cancer, Br. J. Cancer, 73, 1529, 10.1038/bjc.1996.288 Guowei, 2019, The diagnostic efficacy of CYFRA21-1 on intrahepatic cholangiocarcinoma: a meta-analysis, Clin .Res. Hepatol. Gastroenterol., 43, 266, 10.1016/j.clinre.2018.10.010 Abdullah, 2012, The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening, Acta Med. Indones., 44, 94 Hathurusinghe, 2007, Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy, Ann. Surg Oncol., 14, 2714, 10.1245/s10434-007-9481-x Zhang, 2014, Tumor M2-pyruvate kinase in stool as a biomarker for diagnosis of colorectal cancer: a meta-analysis, J. Cancer Res. Therapeut., 10, 225, 10.4103/0973-1482.145886 Banales, 2019, Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis, Hepatology, 70, 547, 10.1002/hep.30319 Macias, 2020, A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma, Cancers, 12, 12, 10.3390/cancers12061433 Haznadar, 2019, Urinary metabolites diagnostic and prognostic of intrahepatic cholangiocarcinoma, Cancer Epidemiol. Biomarkers Prev., 28, 1704, 10.1158/1055-9965.EPI-19-0453 Liang, 2016, Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma, Mol. Biosyst., 12, 334, 10.1039/C5MB00572H Ballman, 2015, Biomarker: predictive or prognostic?, J. Clin. Oncol., 33, 3968, 10.1200/JCO.2015.63.3651 Sicklick, 2019, Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study, Nat. Med., 25, 744, 10.1038/s41591-019-0407-5 Abou-Alfa, 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol., 21, 671, 10.1016/S1470-2045(20)30109-1 Bekaii-Saab, 2020, FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements, Future Oncol., 16, 2385, 10.2217/fon-2020-0429 Makawita, 2020, Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial, Future Oncol., 16, 2375, 10.2217/fon-2020-0299 Borad, 2020, A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearra, J. Clin. Oncol., 38, 10.1200/JCO.2020.38.4_suppl.TPS600 Hollebecque, 2020, A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations, J. Clin. Oncol., 38, 10.1200/JCO.2020.38.4_suppl.TPS470 Zhu, 2021, Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation, J. Clin. Oncol., 39, 10.1200/JCO.2021.39.3_suppl.266 Lee, 2012, Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study, Lancet Oncol., 13, 181, 10.1016/S1470-2045(11)70301-1 Lubner, 2010, Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study, J. Clin. Oncol., 28, 3491, 10.1200/JCO.2010.28.4075 Wainberg, 2019, Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial, J. Clin. Oncol., 37, 10.1200/JCO.2019.37.4_suppl.187 Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J. Clin. Oncol., 38, 1, 10.1200/JCO.19.02105 Arkenau, 2018, Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF), Oncol., 23, 10.1634/theoncologist.2018-0044 Oh, 2022, A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1, J. Clin. Oncol., 40, 10.1200/JCO.2022.40.4_suppl.378 Finn, 2020, Abstract CT283: KEYNOTE-966: a randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma, Cancer Res., 80, 10.1158/1538-7445.AM2020-CT283 Zheng, 2022, Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity, Front. Immunol., 13, 10.3389/fimmu.2022.1093403 Job, 2020, Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma, Hepatology, 72, 965, 10.1002/hep.31092 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet., 51, 202, 10.1038/s41588-018-0312-8 Zhang, 2021, Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma, BMC Cancer, 21, 112, 10.1186/s12885-021-07788-7 Song, 2022, High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma, World J. Clin. Cases, 10, 790, 10.12998/wjcc.v10.i3.790 Prachayakul, 2022, Diagnostic power of DNA methylation markers suggestive of cholangiocarcinoma in ERCP-based brush cytology, Gastrointest. Endosc., 95, 123, 10.1016/j.gie.2021.07.005 Yang, 2021, DNA methylation markers for detection of cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma, Hepatol. Commun., 5, 1448, 10.1002/hep4.1730 Qiu, 2022, Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes, BMC Med., 20, 64, 10.1186/s12916-021-02197-w Glozak, 2007, Histone deacetylases and cancer, Oncogene, 26, 5420, 10.1038/sj.onc.1210610 Song, 2005, Increased expression of histone deacetylase 2 is found in human gastric cancer, APMIS, 113, 264, 10.1111/j.1600-0463.2005.apm_04.x Zhu, 2004, Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis, Cancer Cell, 5, 455, 10.1016/S1535-6108(04)00114-X Mastoraki, 2020, Contribution of histone deacetylases in prognosis and therapeutic management of cholangiocarcinoma, Mol. Diagn. Ther., 24, 175, 10.1007/s40291-020-00454-x Morine, 2012, Role of histone deacetylase expression in intrahepatic cholangiocarcinoma, Surgery, 151, 412, 10.1016/j.surg.2011.07.038 Sriraks, 2013, Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings, Asian Pac. J. Cancer Prev. APJCP, 14, 2503, 10.7314/APJCP.2013.14.4.2503 Eckschlager, 2017, Histone deacetylase inhibitors as anticancer drugs, Int. J. Mol. Sci., 18, 1414, 10.3390/ijms18071414 Ruefli, 2001, The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species, Proc. Natl. Acad. Sci. U. S. A., 98, 10833, 10.1073/pnas.191208598 Kroesen, 2014, HDAC inhibitors and immunotherapy; a double edged sword?, Oncotarget, 5, 6558, 10.18632/oncotarget.2289 Stiborova, 2012, The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment, Curr. Med. Chem., 19, 4218, 10.2174/092986712802884286 Zhou, 2019, miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion, Cancer Biomarkers, 24, 173, 10.3233/CBM-181980 Akazawa, 2019, Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery, Sci. Rep., 9, 1, 10.1038/s41598-019-42392-7 Zhang, 2015, Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis, BMC Cancer, 15, 1 Deng, 2017, Increased expression of miR-29a and its prognostic significance in patients with cholangiocarcinoma, Oncol. Res. Treat., 40, 128, 10.1159/000455869 Li, 2017, MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma, Hepatology, 66, 136, 10.1002/hep.29116 Wang, 2016, N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway, Hepatology, 64, 1606, 10.1002/hep.28781 Li, 2015, Prognostic significance of microRNA-203 in cholangiocarcinoma, Int. J. Clin. Exp. Pathol., 8, 9512 Qiao, 2015, microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway, BMC Cancer, 15, 10.1186/s12885-015-1359-x Chen, 2011, miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma, Dig. Dis. Sci., 56, 1693, 10.1007/s10620-010-1481-1 Zhou, 2019, miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion, Cancer Biomarkers, 24, 173, 10.3233/CBM-181980 Silakit, 2014, Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator, J. Hepatobil Pancreat. Sci., 21, 864, 10.1002/jhbp.145 Wang, 2015, Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma, Oncotarget, 6, 18631, 10.18632/oncotarget.4072 Plieskatt, 2014, Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke Opisthorchis viverrini, J. Hepatol., 61, 850, 10.1016/j.jhep.2014.05.035 Oishi, 2012, Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and EMT in intrahepatic cholangiocarcinoma, Hepatology, 56, 1792, 10.1002/hep.25890 Yao, 2020, Novel miRNA predicts survival and prognosis of cholangiocarcinoma based on RNA-seq data and in vitro experiments, BioMed Res. Int., 2020, 10.1155/2020/5976127 Huang, 2013, MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis, Asian Pac. J. Cancer Prev. APJCP, 14, 829, 10.7314/APJCP.2013.14.2.829 Kondo, 2014, Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma, J. Surg. Oncol., 110, 422, 10.1002/jso.23666 Hu, 2016, Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma, SpringerPlus, 5, 1, 10.1186/s40064-016-2181-x Yamashita, 2017, Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer, Br. J. Surg., 104, 267, 10.1002/bjs.10415 Lee, 2021, Prognostic impact of perioperative CA19-9 levels in patients with resected perihilar cholangiocarcinoma, J. Clin. Med., 10, 10.3390/jcm10071345 Lee, 2015, Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma, Ann. Oncol., 26, vii121, 10.1093/annonc/mdv472.70 He, 2018, Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma, J. Cancer, 9, 3117, 10.7150/jca.25339 Uenishi, 2008, Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma, Ann. Surg Oncol., 15, 583, 10.1245/s10434-007-9650-y Kashihara, 1998, Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level, J. Gastroenterol., 33, 447, 10.1007/s005350050112 Tao, 2010, Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma, Am. Surg., 76, 1210, 10.1177/000313481007601119 Laohaviroj, 2016, Clinicopathological significance of osteopontin in cholangiocarcinoma cases, Asian Pac. J. Cancer Prev. APJCP, 17, 201, 10.7314/APJCP.2016.17.1.201 Zheng, 2018, Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin, Cell Death Dis., 9, 10.1038/s41419-017-0226-x Sulpice, 2013, Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma, Hepatology, 58, 1992, 10.1002/hep.26577 Zhou, 2019, Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma, Hepatobiliary Surg. Nutr., 8, 582, 10.21037/hbsn.2019.03.14 Loosen, 2017, Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma, J. Hepatol., 67, 749, 10.1016/j.jhep.2017.06.020 Takeuchi, 2010, Circulating tumor cells in gastrointestinal cancer, J. Hepatobil Pancreat. Sci., 17, 577, 10.1007/s00534-009-0193-4 Bidard, 2016, Circulating tumor cells in breast cancer, Mol. Oncol., 10, 418, 10.1016/j.molonc.2016.01.001 Giovannoni, 2016, Circulating tumor cells and cholangiocarcinoma, Hepatology, 63, 23, 10.1002/hep.28152 Yang, 2016, Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma, Hepatology, 63, 148, 10.1002/hep.27944 Arnoletti, 2017, Portal venous blood circulation supports immunosuppressive environment and pancreatic cancer circulating tumor cell activation, Pancreas, 46, 116, 10.1097/MPA.0000000000000667 Arnoletti, 2018, Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation, Cancer Biol. Ther., 19, 887, 10.1080/15384047.2018.1480292 Reduzzi, 2020, A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer, Int. J. Cancer, 146, 3495, 10.1002/ijc.32822 Gopinathan, 2020, Exploring circulating tumor cells in cholangiocarcinoma using a novel glycosaminoglycan probe on a microfluidic platform, Adv. Healthc. Mater., 9, 10.1002/adhm.201901875 Chelakkot, 2020, An immune–magnetophoretic device for the selective and precise enrichment of circulating tumor cells from whole blood, Micromachines, 11, 560, 10.3390/mi11060560 He, 2016, TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors, Oncotarget, 7, 75441, 10.18632/oncotarget.12254 Wang, 2018, Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse, Cancer Lett., 412, 99, 10.1016/j.canlet.2017.10.004 Goeppert, 2013, Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer, Br. J. Cancer, 109, 2665, 10.1038/bjc.2013.610 Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N. Engl. J. Med., 348, 203, 10.1056/NEJMoa020177 Mahmoud, 2011, Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer, J. Clin. Oncol., 29, 1949, 10.1200/JCO.2010.30.5037 Vigano, 2019, Tumor-infiltrating lymphocytes and macrophages in intrahepatic cholangiocellular carcinoma. Impact on prognosis after complete surgery, J. Gastrointest. Surg., 23, 2216, 10.1007/s11605-019-04111-5 Yugawa, 2021, Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes, Mod. Pathol., 34, 798, 10.1038/s41379-020-00702-9 Kim, 2021, Serum dickkopf-1 in combined with CA 19-9 as a biomarker of intrahepatic cholangiocarcinoma, Cancers, 13, 1828, 10.3390/cancers13081828 Liu, 2018, Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma, J. Cancer Res. Therapeut., 14, 220, 10.4103/0973-1482.193125 Wang, 2015, The prognostic role of SOCS3 and A20 in human cholangiocarcinoma, PLoS One, 10 Thongsom, 2016, YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma, Tumor. Biol., 37, 9451, 10.1007/s13277-016-4838-z Hirashita, 2012, Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma, J. Gastrointest. Surg., 16, 842, 10.1007/s11605-011-1813-2 Itatsu, 2008, Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts, Hum. Pathol., 39, 710, 10.1016/j.humpath.2007.09.016 Thummarati, 2012, High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis, World J. Gastroenterol., 18, 244, 10.3748/wjg.v18.i3.244 Loosen, 2020, Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer, JHEP Reports, 2, 10.1016/j.jhepr.2020.100080 Onsurathum, 2018, Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma, Tumor Biol., 40, 10.1177/1010428318767195 Wu, 2020, Overexpression of 14-3-3 δ predicts poor prognosis in extrahepatic cholangiocarcinoma patients, BioMed Res. Int., 2020, 1 Li, 2016, Prognostic role of mucin antigen MUC4 for cholangiocarcinoma: a meta-analysis, PLoS One, 11, 10.1371/journal.pone.0157878 Matull, 2008, MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer, Br. J. Cancer, 98, 1675, 10.1038/sj.bjc.6604364 Boonla, 2003, Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma, Cancer, 98, 1438, 10.1002/cncr.11652 Ruzzenente, 2014, A novel serum marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC), Surgery, 155, 633, 10.1016/j.surg.2013.12.003 Khansaard, 2014, Increased EphB2 expression predicts cholangiocarcinoma metastasis, Tumor Biol., 35, 10031, 10.1007/s13277-014-2295-0 Chang, 2019, Plasma proteome plus site‐specific N ‐glycoprofiling for hepatobiliary carcinomas, J. Pathol. Clin. Res., 5, 199, 10.1002/cjp2.136 Weeraphan, 2019, Phosphoproteome profiling of isogenic cancer cell‐derived exosome reveals HSP90 as a potential marker for human cholangiocarcinoma, Proteomics, 19 Büttner, 2021, Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis, Int Hepato-Pancreato-Biliary Assoc., 23, 25, 10.1016/j.hpb.2020.07.007 Wang, 2013, Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy, J. Clin. Oncol., 31, 1188, 10.1200/JCO.2012.41.5984 Song, 2013, Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy, Int. J. Radiat. Oncol. Biol. Phys., 87, 499, 10.1016/j.ijrobp.2013.06.2041 Chen, 2016, Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma, Oncotarget, 7, 37319, 10.18632/oncotarget.9104 Huang, 2022, Establishment and validation of a nomogram for predicting overall survival of node-negative perihilar cholangiocarcinoma, Asian J. Surg., 45, 712, 10.1016/j.asjsur.2021.07.039 Ma, 2021, A novel prognostic nomogram for gallbladder cancer after surgical resection: a single-center experience, JAMA Oncol., 2021 Hyuck Kim, 2017 Zhao, 2019, A prognostic nomogram for distal bile duct cancer from Surveillance, Epidemiology, and End Results (SEER) database based on the STROBE compliant, Medicine (Baltim.), 98 Van der Gaag, 2012, Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 23, 2642, 10.1093/annonc/mds077 Son, 2020, Quantitative proteomic analysis of bile in extrahepatic cholangiocarcinoma patients, J. Cancer, 11, 4073, 10.7150/jca.40964 Urman, 2020, Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: a machine-learning approach, Cancers, 12, 1644, 10.3390/cancers12061644 Oh, 2022, Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer, NEJM Evid, 1, 10.1056/EVIDoa2200015